Vyriad said it will showcase its G-Link modular CAR T delivery platform at the American Society of Gene & Cell Therapy (ASGCT) meeting in Boston. The company described G-Link as a plug-and-play protein adapter that works with existing lentiviral vectors to enable in vivo retargeting and capping without extensive vector re-engineering. Vyriad said the collaboration for G-Link involved Menachem Rubenstein, PhD, of the Weizmann Institute. Mechanistically, the platform is intended to shorten development timelines for next-generation in vivo CAR T and other cell therapies while also simplifying ex vivo manufacturing and improving T-cell transduction efficiency. The company paired the platform update with a pipeline note that its in vivo CAR T program VV169 will progress into clinical development later this year. Vyriad framed G-Link as a way to replace multi-week manufacturing cycles with more off-the-shelf approaches. In the gene-therapy and cell-therapy tooling market, the announcement matters because delivery is often the bottleneck; a reusable adapter strategy could reduce cost and cycle time if it translates into consistent targeting performance in clinical studies.